Search results
Showing 1006 to 1020 of 1254 results for criteria
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.
Patient Status Engine for wireless monitoring of vital signs (MIB271)
NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.
View recommendations for HTG757Show all sections
This quality standard covers recognising, assessing and managing bipolar disorder in adults (aged 18 and over) in primary and secondary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS95Show all sections
Sections for QS95
- Quality statements
- Quality statement 1: Referral for specialist mental health assessment
- Quality statement 2: Personalised care plan
- Quality statement 3: Involving carers in care planning
- Quality statement 4 (developmental): Psychological interventions
- Quality statement 5: Maintaining plasma lithium levels
- Quality statement 6: Valproate
- Quality statement 7: Assessing physical health
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)
Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]
In development Reference number: GID-TA11913 Expected publication date: TBC
In development Reference number: GID-TA11909 Expected publication date: TBC